Skip to main content
Home

Site Map

REPLAGAL® patient website

REPLAGAL® for the treatment of Fabry disease

Living with Fabry disease

Job code: C-ANPROM/GB/REP/0059 Date of preparation: March 2023

Footer home

  • Privacy Notice
  • Terms of Use
  • Contact Us

Takeda Logo

IMPORTANT NOTICE: This information is intended only for UK patients who have been prescribed REPLAGAL® 
(agalsidase alfa) by a healthcare professional.

Initiated and funded by Takeda UK Ltd. © 2023 Takeda Pharmaceutical Company Limited. All rights reserved. Takeda and the Takeda Logo are trademarks of Takeda Pharmaceutical Company Limited, used under license.